

The only realistic way to make 10,525% on a Single Investment

Dear Investor,

A few weeks ago, I had dinner with Dr. George Lowell, one of the world's leading scientists.

We ate at Morton's Steakhouse, near the Pentagon in Alexandria, Virginia.

Over dinner, Dr. Lowell and I talked about a new technology his company has perfected - it could very well be the medical development of the decade. I've been in the business of analyzing medical developments for the past 15 years, so that's not a claim I make lightly.

In the next 12 months, I believe Dr. Lowell's technology will make him - and other early investors - extremely rich.

Just to give you an idea of it's potential... This company's stock price has is up 171% since the beginning of this year. And it still costs less than \$15 a share.

Dr. Lowell, by the way, spent 20 years at the Army's Walter Reed Hospital in Washington D.C., where he made vaccines for U.S. soldiers. For the last 10 years, he's been the Chief Scientific Officer for a small biotech firm located outside of Seattle.

Before I explain the details of Dr. Lowell's breakthrough, and show you how to take advantage of it and other opportunities like it, let me address one important point: I know biotech is off the radar for most investors.

That's for good reason. Because most new drugs fail. Plus, medical terminology can be extremely difficult to understand.

Some applications of biotechnology, however, are really quite simple.

Let me give you an example...

In the mid-1980s, a company called Amgen discovered a gene that helps your body make new red blood cells. They created a clone of this gene, called "EPO."

This isn't a typical chemical drug.

It's a natural protein your body lacks if you have suffered kidney damage, or if you are undergoing chemotherapy. EPO is so safe and simple it was approved by the FDA in 1989 - just four years after it was discovered. (Most new drugs take 10 years or more of testing before they can be sold on the open market.)

EPO has become the best-selling biotech drug of all time. It turned

"Vaccine Business Booming..."

- The Economist,
May 24, 2003:

"The vaccine business is booming. Mother Nature is also giving vaccine-makers a boost. Ageing populations in

Amgen into the largest biotech company in the world (which today is worth \$81 billion).

If you purchased shares of Amgen in 1988, before the FDA approved EPO, you would have made 10,525% profits as of today.

Of course, in hindsight it's easy to see that early Amgen investors didn't take a big risk at all.

They were dealing with a naturally occurring protein that has zero side effects - and tremendous benefits.

Over dinner recently, Dr. Lowell and I discussed a medical development with similar qualities. And with similar investment potential.

Will Dr. Lowell's company do as well as Amgen? I can't promise that it will, but it is certainly one of the best investment opportunities I've ever seen. A 10-20 times return is not at all unrealistic.

Let me explain all of the details, and how our monthly investment advisory works. Then, you can decide for yourself whether or not this is an investment you might want to pursue.

How to stop smallpox, the plague... even the flu

What Dr. Lowell and I talked about is a new vaccine.

It is now being used to prevent Strep Throat, the flu, allergies, and the plague (one of the worst bioterrorism agents in the world). Ultimately, it could be used to stop the common cold, and just about

the rich world are increasingly offered flu vaccines by governments keen to keep health-care bills low... Fear of bioterrorism is also helping."

every bioterrorism threat there is, from smallpox to Anthrax.

In short, this biomedical development is actually a whole new way of creating and delivering all kinds of vaccines. It's called Proteosome Technology.

I believe this could be the most important vaccine breakthrough of the past 50 years. As I'll show you, it's not hard to see why Proteosome Vaccines are so valuable - and how they could offer such a great payday for early investors.

The safest and most effective vaccine in the world

Proteosomes, to give you just a little background, are basically groupings of three harmless "sticky" fat molecules.

The big difference between Proteosome vaccines and today's standard vaccines is that Proteosome vaccines do not require the "live" version of whatever it is you are trying to prevent - which is how today's vaccines typically work.

"Sales Booming..."
- Reuter's Business,
Jan 07, 2003

"Sales of vaccines, once considered a commodity market, are booming with global revenues set to reach nearly \$10

Plus, instead of administering them with a needle, you can simply sniff Proteosome vaccines through a tiny, hand-held inhaler. Much like you would do with today's allergy medications.

You could, in other words, pick up a Proteosome vaccine at your local pharmacy, and administer it yourself. No more doctors... nurses... or painful needles required.

billion in 2006 from \$5.4 billion in 2001, according to research published on Tuesday.

"Analysts at Merrill Lynch said the fastest growing section of the market would be for flu vaccines, sales of which are expected to more than double to \$2 billion in the next five years."

Proteosome vaccines have other tremendous advantages over today's needle vaccines:

1) They are safer. As I mentioned, Proteosome vaccines are not based on a "live" version of a real virus. This means there's absolutely no way to get infected from a Proteosome vaccine. You've probably heard about soldiers and health officials getting infected from the current small pox vaccine being used. This simply **COULD NOT** happen with a Proteosome Vaccine.

2) Proteosome Vaccines work better. Proteosome vaccines circulate in the blood and in the respiratory system. That means they can fight invading microbes no matter how they enter your body. (Today's regular vaccines can protect only your blood.)

3) Proteosome Vaccines are more durable. You can, for example, store Proteosome vaccines at room temperature (most ordinary vaccines must remain frozen). You can freeze, thaw, refreeze, thaw...it doesn't matter. They'll still work. This means these vaccines could ultimately be sold as over-the-counter medications. You might not even have to sit in the waiting room of your doctor's office.

Finally, and most importantly, Proteosome vaccines can potentially be used to treat anything that affects your respiratory tract (your nose, throat, and lungs). And could ultimately be used to administer almost every vaccine used today.

This means the technology could provide protection from everything

from the flu to Strept throat, HIB, Typhoid fever and Dysentery... from AIDS to Anthrax, smallpox and the plague.

Dr. Lowell's company has used vaccines in the clinic to fight flu, plague, and dysentery. In animal experiments, they've used proteosomes to fight AIDS, allergies, and even the common cold.

This technology has been proven 100% effective in preventing the flu (Source: *SA Halperin, et al. "Phase I Safety and Immunogenicity of FluInsure, a Proteosome-trivalent Influenza Vaccine Given nasally to Adults," presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, CA. September 30th, 2002.*), and most recently was proven to be 100% effective in preventing mice from being infected with the plague (Source: *"Nasal immunization with Plague antigen formulated with the Proteosome technology," sponsored by the National Foundation for Infectious Diseases, revealed May 20, 2003 in Washington, DC by Dr. Jefferey Adamovicz, LTC US Army, at the American Society for Microbiology, 103rd General Meeting*).

"The Big One" for 2003

Every year since Porter started his private investment advisory service, he's looked for the biggest and best investment opportunity of the year.

I believe that if you're going to have a good year with your portfolio, you've got to have at least one big winner, to make up for any small losses.

- **In 1999**, his "Big One" was Qualcomm: We made profits of 1,300%, using a trailing stop that allowed us to get out of the stock before it collapsed.
- **In 2000**, our "Big One" was JDS Uniphase. We

Are you beginning to see why this could be such a giant medical breakthrough? The vaccine for each of these ailments could be worth billions of dollars on their own. Added together, the numbers are astronomical.

This company could DOMINATE the vaccine market - and today you can buy it for less than \$15 a share.

The 5 facts you need to know

I've covered a fair amount of scientific material so far. And there's a lot more scientific data I'd like to show you.

But as a potential investor, there are really just 5 important facts you need to know:

FACT #1: This is the vaccine development of the decade. Dr. Lowell's company has developed a breakthrough method of making and delivering vaccines, using something called Proteosome Technology.

It's safer, more effective, more durable, cheaper, and easier to use than current vaccination methods. Ultimately it can be used to stop the

made 930%, again because of our trailing stop, which we'll show you how to use.

- **In 2001**, the "Big One" was a short of AT&T. The company's stock has lost 85% of it's value since then, giving us huge profits.
- **In 2002**, the 'Big One' involved the collapse of a handful of companies. We made profits of 54.5% on Imclone and 54.1% on Northwest Airlines, just to name a few.
- **For 2003 and 2004**, the "Big One" is the Proteosome Technology company I describe in this report.

If you missed out on the

flu, the common cold, Strept throat, and just about every bioterrorism threat, from smallpox to the plague.

FACT #2: Test results are proven.

This company has preventative vaccines in advanced clinical development to stop the plague, the flu, and Strept throat. From the test results we've seen, THESE VACCINES WORK... and just as importantly, THEY ARE SAFE, according to the U.S. Food and Drug Administration and Health Canada.

"Big Ones" of the past, it's not too late to take advantage of this one. **See below for full details.**

FACT #3: Billions in sales per year. Each vaccine on its own could be worth billions in revenue, every single year. Strept throat alone has a \$4 billion impact in the United States each year. And according to the U.S. Centers for Disease Control and Prevention, we need about 93 million doses of flu vaccine in the United States every year.

"Project Bioshield is Big Incentive To Vaccine Makers"

- The Wall Street Journal, January 30th, 2003

President Bush recently announced Project Bioshield, a \$6 billion initiative to pay for new drugs and vaccines

FACT #4: The U.S. Army is already on board. The U.S. Army has already given this company \$6 million to work on vaccines to prevent bioterrorism. Plus, British troops used the "building blocks" of this technology to prevent infection during the recent war against Iraq (Source: Brady, Brian, "Troops to get Saddam Plague Jab," *Scotland on Sunday*, October 27, 2002.)

FACT #5: Today it's very cheap.

This company is currently worth only \$600 million in the stock market. You can buy it for less than \$15 a share

combating bio-weapons.

This couldn't come at a better time for the company that is finalizing Proteosome Technology - the biggest vaccine development of the decade.

Project Bioshield does three things:

#1. It gives money - lots of it...in the neighborhood of \$6 billion - to buy vaccines for smallpox, anthrax, botulism, Ebola, and plague.

#2. It forces government agencies such as the National Institutes of Health (NIH) to speed up the processing of grants (more money!) to support the companies researching new vaccines and treatments.

today.

For these reasons, I believe this company offers you the only realistic chance in the stock market to make 10-20 times your money in the short term.

The kind of work your broker should be doing - But isn't

My name, by the way, is David Lashmet. I'm an equity analyst. My specialty is biotechnology.

I work for a fellow named Porter Stansberry. Together, Porter and I find breakthrough technology investment opportunities. It's something we've worked on together for almost 10 years.

I've been following this Proteosome vaccine company for almost three years personally. I check in with them just about every week. And just so you know a little more about me... I'm finishing up my PhD in Medical Cultural Studies, and have spent the past 15 years analyzing medical technologies and infectious diseases for universities, the U.S. military, and private industry.

#3. It allows the Food and Drug Administration (FDA) to move more quickly to approve bioterrorism drugs and vaccines.

Project Bioshield could save countless lives.

And it will mean one thing for investors in the best vaccine company in the world: Bigger, quicker profits.

I first visited this small vaccine company's research headquarters over two days in August of 2000. Porter and I have been following it closely ever since.

When they built a vaccine manufacturing facility, for example, I was one of the first outsiders to tour it. Porter and I have done follow-up research at conferences and universities all over the country. I also went through the Continuing Medical Education (CME) course set up for doctors to learn about flu vaccines and nasal delivery.

Overall, Porter and I have reviewed dozens of individual scientific articles and studies on this company's work.

We've put together 10 separate summary reports of our own, and have spent more than 250 hours analyzing the company's fundamentals. We've read the company's key publications and patents. We know all the important scientists and business managers on a first-name basis.

As I mentioned earlier, I met the company's most important scientist, Dr. George Lowell, for dinner just a few weeks ago near the Pentagon.

Despite these connections, we remain objective.

We don't get anything from them... and they don't get anything from us.

This is the kind of legwork that gives us a huge advantage over the average investor. I think it's the only safe way to invest in biotech companies. And it's work your investment advisor and broker simply don't have the time or resources to do.

We're recommending this Proteosome vaccine company because we believe it is the single best opportunity in the stock market for the next 12 months.

How a stock goes up 10 times or more in price

You may think I'm exaggerating when I tell you that you could make 10-times your money with this company. But in the business of medicine, gains like that are ordinary - if you find the right opportunity.

It happens over and over again in the world of new drugs:

1. A small medical company introduces a valuable new medicine or treatment.
2. The FDA approves it.
3. Early investors get rich.

For example...

- I explained how Amgen developed a new drug called EPO for cancer patients. Early investors made more than 10,000% profits if they held the stock until today.
- After Biogen launched its drug Avonex to treat multiple sclerosis in 1996, its stock shot up 667%
- When Idec Pharmaceuticals, a San Diego biotech company, introduced its cancer-tumor shrinking drug Rituxan, its stock went from \$2 to \$125. That's an increase of 6,150%!

The list goes on and on. And remember, a new way to make and deliver vaccines would apply to literally hundreds of ailments: the flu, Strept throat, whooping cough, AIDS, smallpox, the plague, and many, many more.

What to do now:

I recommend you buy shares of this company right away, while it's still unbelievably cheap.

Of course, there's no guarantee these vaccines will pass the final test. Or that the government will grant FDA approval if they do. That means this investment is not for everyone, because you could lose money. All I can guarantee are the facts I've just outlined. And the evidence we've seen over the past three years. The risk-to-reward ratio, we believe, is outstanding.

Keep in mind, you need only a very small investment to have the potential for a huge payoff. In fact, I recommend you never put more than 4% of your portfolio into any one investment.

Believe me, if this company takes off as I expect, even a small investment will produce tremendous profits.

If you are interested in pursuing this opportunity, I will send you a full Investigative Analysis, called ***Proteosome Technology - The Vaccine Development of the Decade***, which details 1) the studies that prove this technology works 2) the people behind this company, 3) what will happen with this company over the next 12 months, and 4) what you should do right now.

We have charged as much as \$1,000 to provide investors with research this thorough. I think it's a reasonable fee, considering 1) the level of work that goes into it and 2) the profit potential. By my estimates, we've spent more than \$250,000 on this research,

including salaries and travel expenses.

For people who want to receive our top technology selections throughout the year, we charge a discounted rate of \$5,000 for 12 comparable reports, delivered throughout the year.

But here is good news for you.

Instead of paying \$1,000 to receive this research, you have the opportunity to receive the full details on the Proteosome Vaccine company simply by subscribing to our monthly newsletter research service, called **Porter Stansberry's Investment Advisory**.

How to recover what you've lost in the stock market

Let me show you exactly how Porter's Investment Advisory works, and what you can expect as a subscriber, so you can decide whether or not it makes sense for you.

**"More money
than I've ever
made..."**

"I'm the Chief of Vascular Surgery at the Stanford Medical Center. I'm retiring and leaving my practice after 40 years. I want you to know that on your advice...I've made more

Each month, Porter and I report not only on new medical technologies, but also the other important technology sectors of the economy: energy, telecom, semiconductors and software, just to name a few.

Porter does a heck of a lot of traveling (about 125,000 air miles per year) to attend technology conferences, to visit companies we're interested in, and to investigate foreign business operations. (See the box on the next screen for more details.)

money in the last six months than I have ever made on any other stock I have ever owned. You've made me the hero of my investment club."

- Dr. Edmund J. Harris,
California

And I do a lot of traveling too.

Next week, for example, I'll be in Chicago for the American Society of Clinical Oncologists' (ASCO) meeting. There are four important studies that will be reported on. As a subscriber to our advisory newsletter, you'll know which of these developments might make good investments, and which you should avoid altogether.

All of this travel means that, between the two of us, we come across many opportunities you won't read about anywhere else.

When you subscribe to Porter's service, we'll send you a complete report the first week of every month by e-mail. A hard copy of this report will arrive in your mailbox about a week and a half later. It will contain updates on our current investments, and details on what we've been investigating.

Everything we recommend comes with the same thorough, from-the-ground-floor perspective you've read here.

I think we can help you gain a huge advantage over 99.9% of the investors out there. Especially when it comes to new technologies. That's our specialty. For example...

- Most Wall Street analysts covering Kodak - the chemical film company - didn't know anything about Adobe, a software company that specializes in digital images.

"The best stock newsletter I've ever read..."

It was clear to Porter as early as 1998 that chemical film was a thing of the past. So, he recommended that investors SELL Kodak and BUY Adobe. Kodak plummeted from \$80 per share to \$30. Adobe has doubled, from \$15 to over \$30.

The same scenario happened in telecommunications...

- Most investors still consider the Baby Bells to be safe haven investments - recession proof. But as we've shown our readers in recent months, AT&T's fate (it's dropped about 62% in the past two years) awaits the Baby Bells.

We recommended short-selling one Baby Bell, for example, Bell South. Today it's about half the price it was only a year and a half ago.

- **And it's happening again in the retail sector.** Everyone knows K-Mart was struggling for a long time, and finally filed for bankruptcy. But most people don't know that ANOTHER one of the biggest discount retail businesses in the country is in serious trouble. Sure, it's still a great place to shop for everything from electronics to clothing - just DON'T OWN THE STOCK. It's already dropped 10% since

"Let me say I am totally delighted with your newsletter. I will go further. I will say it is absolutely the best stock newsletter I have ever subscribed to. I got my Ph.D in Electrical Engineering from Stanford University in 1970.

Since then, I have written 10 textbooks in electronics and computers that have been translated into 20 foreign languages with over 108 editions. When it comes to presenting solid investment ideas to consider, yours is by far the best stock newsletter I have ever read. Keep up the great work."

- Dr. Albert P. Malvino,
Ph.D

our recommendation to sell, and still has a long way to go.

We'll give you the complete explanation when you subscribe to...

[*read on*](#)